

In claim 8, line 2, delete "characterized in that" and insert in place thereof -- wherein --.

REMARKS

The telephonic requirement for restriction between:

Group I: Claims 1-5, 7, and 9-25, and
Group II: Claim 6

by the Examiner on July 1, 1999 and Applicants' election, with traverse, of the subject matter of Group I is hereby acknowledged. The Examiner has also indicated that the process of claim 8 will be examined with Group I if the product claims of Group I are found to be allowable.

Claim 1 has been amended in order to correct an obvious typographical error.

Claims 7 and 8 have been amended in order to replace the phrase "characterized in that" with the word "wherein" in order to write these claims in the appropriate U.S. claim format.


Claim 7 has also been amended in order to correct a typographical error in the portion of the chemical name reading as "ethyl)oxycyclohexane]", which now correctly reads as "ethyloxy)cyclohexane]". Support for this amendment occurs, for example, on page 13, lines 29-31 of the specification wherein the compound is correctly named.

Claim 7 has also been amended in order to correct a typographical error in the portion of the chemical name reading as "(N-*tert*-amylbutylcarbamoyl)", which now correctly reads as "(N-*tert*-amylcarbamoyl)". Support for this amendment occurs, for example, on page 14, lines 10-12 of the specification wherein the compound is correctly named.

Respectfully submitted,

Dated: July 9, 1999

Sanofi Pharmaceuticals, Inc.
Patent Department
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355
Tel.: (610) 889-8802
Fax: (610) 889-8799


MICHAEL D. ALEXANDER
Registration No. 36,080

